• Toolbox
    • Terms and conditions
    • Glossary
    • Sitemap
  • Home
  • About us
  • Development
  • Research
  • Partnering
  • Investor centre
  • Media centre
  • Contact us
Home Toolbox Sitemap
  • Toolbox
    • Terms and conditions
    • Sitemap
    • Glossary

Sitemap

  • Home
  • About us
    • Overview
    • Vision and strategy
    • Our people
      • Board of directors
      • Senior management
    • History
    • Careers at Vernalis
    • Corporate social responsibility
  • Development
    • Pipeline Overview
    • CNS
      • Frovatriptan
      • V158866
      • V81444
    • Oncology
      • AUY922
      • CHR2797
      • HSP990
      • V158411
    • Other Therapeutic Areas
      • V85546
    • Legacy Programmes
      • RPL554
  • Research
    • Overview
    • Vernalis Strengths
      • Team
    • Fragment- and Structure-Based Drug Design
    • Oncology
    • Collaborations
    • Publications
  • Partnering
    • Overview (why partner?)
    • In-Licensing
    • Out-Licensing
      • V85546
    • Research collaborations
    • Conferences
    • Current partners
  • Investor centre
    • Shareholder information
      • Key facts
      • Share price information
      • Advisors and Investor contacts
      • Analyst coverage
      • Shareholder services
      • ADR programme
      • FAQs
    • Financial reports and accounts
    • Presentations and webcasts
    • Corporate governance
    • Anticipated Newsflow
    • Regulatory announcements
  • Media centre
    • Latest releases
      • 2010 releases
    • Regulatory announcements
    • Archive releases
      • 2009 releases
      • 2008 releases
      • 2007 releases
      • 2006 releases
      • 2005 releases
      • 2004 releases
      • 2003 releases
    • Presentations and webcasts
    • Media contacts
  • Contact us
    • Contact information
    • Maps and directions
    • Contact form

© 2012 Vernalis All Rights Reserved

  • Terms and conditions
  • Privacy policy
  • Glossary
  • Company registration and address details